Ticagrelor and clopidogrel were found to be associated with comparable long-term net adverse clinical events among patients who underwent PCI for ACS.
Current guidelines recommend a 12-month-long DAPT to reduce the risk for ischemic and thrombotic events following percutaneous coronary intervention.
Dose de-escalation of prasugrel 1 month after percutaneous coronary intervention in patients with acute coronary syndrome was found to lower the risk for adverse clinical outcomes.
In the BETonMACE trial, CKD patients with type 2 diabetes who recently experienced acute coronary syndrome who received apabetalone had a significant 50% reduction in the risk for major cardiovascular events compared with placebo.
BNP or NT-proBNP may represent effective markers for the prediction of contrast-induced acute kidney injury in patients with acute coronary syndrome undergoing coronary angiography.
STS was found to be well-tolerated and safe in combination with vasodilatory and blood pressure-lowering drugs in patients with ACS undergoing coronary angiography.
Endocan level was found to be an independent predictor of the no-reflow phenomenon during primary percutaneous coronary intervention for STEMI.
Ticagrelor and prasugrel may have altered efficacy for the treatment of acute coronary syndrome in patients with diabetes mellitus.
Therapies which improve endothelial dysfunction should be considered for the treatment of patients with COVID-19-and acute coronary syndrome.
For patients with acute coronary syndrome (ACS), hostility predicts all-cause mortality but not recurrence.